BioCentury

Current Editions

SwanBio’s $56M series B reflects hard choices in venture rounds

In a time of depressed valuations, U.K. investor Syncona returns to provide lion’s share of round as CNS gene therapy heads toward human trial

Finance

Product Development

May 18 Quick Takes: Enanta tumbles after hours after missing RSV endpoint

Plus: House E&C passes user fee bill and updates from Hengrui, Laekna, Prenetics, Enanta and more

Data Byte

The more the miserable: biotech stock woes embraced by broader market

Concerns over big retailers’ earnings drag already battered biotech indexes down 

Regulation

Woodcock to focus on modernizing FDA operations

Califf: Principal Deputy Commissioner Woodcock’s focus will not be on medical products

Finance

Series B builds Locus’ spending power for business development

With $35M financing, Locus is searching for expansion opportunities for its CRISPR and bacteriophage platforms

Management Tracks

AbbVie’s Pappalardo joins Fresenius as CMO for North America

Plus SOBI’s Batten joins Veru, and updates from FlandersBio, Google Health, Morphic and more

BioCentury ISSN 1097-7201